Humanigen, Inc. Rings the Opening Bell

ABOUT THIS EVENT

Humanigen, Inc. (Nasdaq: HGEN), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab™, rings the Nasdaq Opening Bell remotely from across the country.

Cameron Durrant, MD, MBA, Chairman & CEO, rings the Opening Bell alongside the Company’s team in a virtual bell ringing ceremony.